📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-24 22:34
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
8 announcements match the current filters (relevance ≥ 5).
Anondita Medicare Allots 9.58 Lakh Equity Shares via ₹91.03 Cr Rights Issue at ₹950/Share
The Board of Directors of Anondita Medicare has approved the allotment of 9,58,166 equity shares of face value ₹10 each at an issue price of ₹950 per share on a rights basis. The total fundraise aggregates up to ₹9,102.58 lakhs (₹91.03 crore). Following this allotment, the company's paid-up equity share capital increased from ₹18,08,66,180 (1,80,86,618 shares) to ₹19,04,47,840 (1,90,44,784 shares). The Rights Issue had opened on September 09, 2026, and closed on September 22, 2026.
Confidence: HIGH
What changedAnondita Medicare finalized the allotment of its rights issue, expanding its outstanding share base from 1,80,86,618 to 1,90,44,784 equity shares.
Why it mattersThe company secures ₹91.03 crore in equity funding to support working capital, regulatory expansions (such as MDSAP markets), or automation, with modest equity dilution of ~5.3%.
Shares allotted: 9,58,166Issue price per share: ₹950Total fundraise value: ₹9,102.58 LakhsPost-issue paid-up capital: ₹ 19,04,47,840Equity base expansion: 5.30%
📅 Short termShort-term impact is driven by the listing and trading liquidity of the 9.58 lakh newly allotted shares.
📈 Long termThe ₹91.03 crore capital infusion strengthens the balance sheet to fund ongoing automation and regulatory entries across targeted global markets.
⚠ Risk flags
- Equity dilution of ~5.3% across existing share capital
- Execution risk on effective utilization of the ₹91.03 crore proceeds
Key Highlights
Approved allotment of 9,58,166 equity shares of face value ₹10 each at ₹950 per share
Total capital raised aggregates up to ₹9,102.58 lakhs (approx. ₹91.03 crore)
Paid-up share capital expanded from ₹18.09 crore to ₹19.04 crore, representing ~5.3% equity dilution
Rights issue closed on September 22, 2026, and allotment finalized on September 24, 2026
👀 What to Watch
Track the listing and credit of newly allotted shares to demat accounts, and monitor management commentary regarding the deployment of the ₹91.03 crore proceeds toward international expansion and capacity.
Anondita Medicare Allots 9.58 Lakh Equity Shares via ₹91.03 Cr Rights Issue at ₹950/Share
The Board of Directors of Anondita Medicare has approved the allotment of 9,58,166 equity shares of face value ₹10 each at an issue price of ₹950 per share on a rights basis. The total fundraise aggregates up to ₹9,102.58 lakhs (₹91.03 crore). Following this allotment, the company's paid-up equity share capital increased from ₹18,08,66,180 (1,80,86,618 shares) to ₹19,04,47,840 (1,90,44,784 shares). The Rights Issue had opened on September 09, 2026, and closed on September 22, 2026.
Confidence: HIGH
What changedAnondita Medicare finalized the allotment of its rights issue, expanding its outstanding share base from 1,80,86,618 to 1,90,44,784 equity shares.
Why it mattersThe company secures ₹91.03 crore in equity funding to support working capital, regulatory expansions (such as MDSAP markets), or automation, with modest equity dilution of ~5.3%.
Shares allotted: 9,58,166Issue price per share: ₹950Total fundraise value: ₹9,102.58 LakhsPost-issue paid-up capital: ₹ 19,04,47,840Equity base expansion: 5.30%
📅 Short termShort-term impact is driven by the listing and trading liquidity of the 9.58 lakh newly allotted shares.
📈 Long termThe ₹91.03 crore capital infusion strengthens the balance sheet to fund ongoing automation and regulatory entries across targeted global markets.
⚠ Risk flags
- Equity dilution of ~5.3% across existing share capital
- Execution risk on effective utilization of the ₹91.03 crore proceeds
Key Highlights
Approved allotment of 9,58,166 equity shares of face value ₹10 each at ₹950 per share
Total capital raised aggregates up to ₹9,102.58 lakhs (approx. ₹91.03 crore)
Paid-up share capital expanded from ₹18.09 crore to ₹19.04 crore, representing ~5.3% equity dilution
Rights issue closed on September 22, 2026, and allotment finalized on September 24, 2026
👀 What to Watch
Track the listing and credit of newly allotted shares to demat accounts, and monitor management commentary regarding the deployment of the ₹91.03 crore proceeds toward international expansion and capacity.
Anondita Medicare Confirms ₹91.03 Cr Rights Issue for 9,58,166 Shares
Anondita Medicare Limited has withdrawn its earlier nullification letter dated September 08, 2026, reinstating the revised Rights Issue parameters. The company confirmed the allotment of 9,58,166 Rights Equity Shares aggregating up to ₹9,102.58 Lakhs (₹91.03 crore) as per the corrigendum dated September 07, 2026. This supersedes the original Letter of Offer dated August 27, 2026, which planned an issue of 9,58,000 shares. All disclosures and submissions for NSE post-allotment in-principle approval will proceed based on the restored 9,58,166 share count.
Confidence: HIGH
What changedThe company restored the September 07 corrigendum, establishing the finalized Rights Issue size at 9,58,166 shares (₹91.03 crore) after previously nullifying it.
Why it mattersResolves administrative ambiguity regarding the exact share count and issue size, clearing the path for post-allotment exchange approvals and capital receipt.
Total Rights Issue Size: ₹9,102.58 LakhsRights Shares Allotted: 9,58,166Original Issue Size (Shares): 9,58,000
📅 Short termEnsures clarity on total shares to be credited and listed; investors should look out for the NSE listing notification.
📈 Long termEquity base expands by 9,58,166 shares; long-term performance depends on deploying the ₹91.03 crore proceeds into stated expansion plans.
⚠ Risk flags
- Shareholder equity dilution resulting from the issuance of 9,58,166 new shares
- Procedural back-and-forth reflects minor administrative turbulence in documentation
Key Highlights
Confirmed allotment of 9,58,166 Rights Equity Shares aggregating up to ₹9,102.58 Lakhs
Withdrew the Nullification Letter dated September 08, 2026, in its entirety
Restored Corrigendum to the Letter of Offer dated September 07, 2026, adjusting issue size by 166 shares from original 9,58,000 shares
Filing will form operative basis for In-Principle Approval (Post Allotment) with NSE
👀 What to Watch
Track the receipt of final listing and trading approvals from the National Stock Exchange for the 9,58,166 allotted shares, as well as deployment of the ₹91.03 crore proceeds.
Anondita Medicare Declared L1 Bidder by CMSS for Supply of 8.00+ Cr Condoms
Anondita Medicare Limited has been declared the lowest (L1) bidder under Schedule 1 by the Central Medical Services Society (CMSS), Ministry of Health and Family Welfare, Government of India. The tender involves the supply of 8,00,62,000 (over 8 crore) pieces of condoms under the national Family Planning Programme (Tender Ref. CMSS/Proc/2026-27/FP/005). While the exact financial value of the contract was not disclosed, this win represents a major volume order for the company's manufacturing operations.
Confidence: HIGH
What changedAnondita Medicare transitioned from tender participant to the declared L1 bidder for an 8.006 crore condom procurement tender by CMSS.
Why it mattersDemonstrates strong institutional procurement capability and secures significant manufacturing volume utilization for the company's production facilities.
Tender Quantity: 8,00,62,000 piecesTender Reference Date: May 6, 2026Contract Value: not disclosed
📅 Short termPositive sentiment likely following the L1 status declaration as markets anticipate the formal purchase order and commercial value details.
📈 Long termStrengthens track record in large-scale public healthcare procurement, complementing its branded retail and international expansion strategies.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Final purchase order / contract award formalization is still pending
- Contract value and realization prices are not disclosed; institutional government tenders typically carry lower gross margins
- Dependency on single manufacturing facility for large-scale execution
Key Highlights
Declared L1 bidder under Schedule 1 by Central Medical Services Society (CMSS)
Tender entails supply of 8,00,62,000 units (8+ crore pieces) of condoms
Issued under Government of India's Family Planning Programme (Tender dated May 6, 2026)
Declaration period finalized in August 2026
👀 What to Watch
Track subsequent filings for the formal issuance of the Letter of Award (LoA), total contract value, execution timelines, and impact on working capital.
Anondita Medicare emerges L1 bidder for 8.006 Cr condom units tender from CMSS
Anondita Medicare Limited has been declared as the L1 (lowest) bidder under Schedule 1 by the Central Medical Services Society (CMSS), Ministry of Health and Family Welfare, Government of India. The tender is for the supply of 8,00,62,000 (8.0062 crore) pieces of condoms under the Free Supply Family Planning Programme. While the final monetary order value is not disclosed, securing this tender represents a substantial volume win for the company's domestic manufacturing operations.
Confidence: HIGH
What changedAnondita Medicare has been declared the lowest (L1) bidder for a major central government procurement tender.
Why it mattersWinning a volume order of 8.006 crore units provides high capacity utilization for manufacturing lines and strong domestic revenue visibility.
Tender quantity: 8,00,62,000 piecesContract value: not disclosedBid status: L1 Bidder
📅 Short termPositive sentiment expected on operational traction; formal contract execution and Letter of Award (LoA) will be key near-term triggers.
📈 Long termDemonstrates capability to win institutional tenders, complementing the company's strategic focus on regulated global markets.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution and delivery timelines pending final contract award
- Pricing/margin pressure inherent in competitive government institutional tenders
Key Highlights
Declared L1 bidder under Schedule 1 by Central Medical Services Society (CMSS)
Tender quantity stands at 8,00,62,000 (8.0062 crore) pieces
Issued under Ministry of Health and Family Welfare for Family Planning Programme
Exact monetary contract value not disclosed in the filing
👀 What to Watch
Track subsequent filings for the formal award of the contract, confirmed commercial order value, and the specified delivery/execution schedule.
Anondita Medicare Files Letter of Offer for ₹91.01 Cr Rights Issue at ₹950/Share
Anondita Medicare Limited has submitted its final Letter of Offer for a Rights Issue of up to 9,58,000 equity shares to raise up to ₹91.01 crore (₹9,101.00 lakhs). The issue price is fixed at ₹950 per share (face value ₹10 plus ₹940 premium) with an entitlement ratio of 97 rights shares for every 1,831 equity shares held. The record date for determining eligible shareholders is September 02, 2026. The issue will open on September 09, 2026, and close on September 22, 2026, with on-market renunciation available until September 11, 2026.
Confidence: HIGH
What changedThe company finalized the complete Letter of Offer, issue calendar, and entitlement terms for its ₹91.01 crore rights issue.
Why it mattersThe fundraise injects fresh equity capital to support business expansion and balance sheet strength, while resulting in dilution for non-subscribing shareholders.
Issue Size: ₹91.01 croreIssue Price per Share: ₹950Number of Rights Shares: 9,58,000Rights Entitlement Ratio: 97:1831Record Date: September 02, 2026Issue Close Date: September 22, 2026
📅 Short termRights Entitlements will be credited by September 04, 2026, with on-market trading of REs expected between September 09 and September 11, 2026.
📈 Long termSuccessful capital raising will support the company's global expansion and compliance goals, though long-term value creation depends on effective deployment.
⚠ Risk flags
- Dilution for existing shareholders who choose not to subscribe
- Subscription and execution risk for planned deployment of proceeds
Key Highlights
Rights issue to raise up to ₹91.01 crore (₹9,101.00 lakhs) via 9,58,000 fully paid equity shares
Issue price set at ₹950 per share (₹10 face value + ₹940 premium)
Rights ratio established at 97 rights shares for every 1,831 existing shares held
Record date fixed as September 02, 2026; issue window spans September 09 to September 22, 2026
Targeted listing of rights equity shares on NSE Emerge platform on or about September 25, 2026
👀 What to Watch
Eligible shareholders should note the September 02, 2026 record date and evaluate whether to subscribe, renounce, or allow their Rights Entitlements to lapse before September 11, 2026 (for on-market trading).
Anondita Medicare approves Rights Issue at ₹950/share to issue 9.58 lakh shares
Anondita Medicare Limited's Board of Directors approved a rights issue of equity shares on August 27, 2026. The rights entitlement ratio has been set at 958000 : 18086618 (9,58,000 equity shares for every 1,80,86,618 shares held) at an issue price of ₹950 per share. The issue will raise approximately ₹91.01 crore if fully subscribed. Alongside, the Board appointed Secretarial, Internal, and Cost Auditors for FY 2026–27.
Confidence: HIGH
What changedThe Board approved a rights issue to raise up to ~₹91.01 crore at ₹950 per share, along with regular auditor appointments for FY 2026-27.
Why it mattersThe capital raise provides fresh equity funding to support ongoing international expansion and production automation initiatives, with minimal equity dilution of ~5.3%.
Issue Price: Rs. 950 per shareShares to be issued: 958000Rights Ratio: 958000 : 18086618Total Issue Size: ₹91.01 cr
📅 Short termExisting shareholders will watch for the announcement of the record date and the detailed terms/timelines of the rights issue window.
📈 Long termIf deployed effectively, the proceeds can strengthen the balance sheet and accelerate the company's global expansion into regulated markets like USA, Brazil, Canada, and Japan.
⚠ Risk flags
- Dilution risk if shareholders do not subscribe
- Execution and market risk in deploying capital effectively across export jurisdictions
Key Highlights
Board approved rights issue of 9,58,000 equity shares
Issue price set at ₹950 per equity share
Entitlement ratio fixed at 958000 : 18086618 shares held (~5.3% share addition)
Total capital to be raised equals approximately ₹91.01 crore
Appointed Secretarial, Internal, and Cost Auditors for FY 2026–27
👀 What to Watch
Track subsequent announcements regarding the rights issue schedule, record date, draft letter of offer, and explicit fund utilization plans.
Anondita Medicare Receives NSE In-Principle Approval for ₹109.78 Cr Rights Issue
Anondita Medicare Limited has secured in-principle approval from the National Stock Exchange of India (NSE) for a proposed Rights Issue of fully paid-up equity shares aggregating up to ₹10,978.20 lakhs (₹109.78 crore). The equity shares will have a face value of ₹10 each. The approval was granted via NSE letter dated August 25, 2026, subject to regulatory compliance and subsequent listing applications.
Confidence: HIGH
What changedNSE has granted in-principle approval for Anondita Medicare to proceed with its proposed ₹109.78 crore rights issue.
Why it mattersThe capital raise of up to ₹109.78 crore will provide substantial equity funding to support the company's manufacturing automation and international market expansion across key regulated geographies.
Total Rights Issue size: ₹10,978.20 lakhsFace value per share: ₹10Approval letter date: August 25, 2026
📅 Short termApproval paves the way for the board to fix the record date, issue price, and ratio, which will determine near-term shareholder dilution and subscription appetite.
📈 Long termIf successfully subscribed, the ₹109.78 crore proceeds could significantly strengthen the balance sheet and finance global expansion strategies across target export markets.
⚠ Risk flags
- Equity dilution for non-participating shareholders upon completion of the rights issue.
- Final terms (issue price, ratio) and full subscription remain pending completion.
Key Highlights
Received NSE in-principle approval on August 25, 2026, for a proposed Rights Issue.
Fundraise size aggregates up to ₹10,978.20 lakhs (₹109.78 crore).
Proposed issue involves fully paid-up equity shares with a face value of ₹10 per share.
Issue price, rights entitlement ratio, and record date are to be finalized and disclosed in due course.
👀 What to Watch
Track subsequent filings for the board's announcement on the rights issue price, entitlement ratio, record date, and fund deployment plans.
